Citation

Geusens PP, Lems WF, Bours S, Vd Bergh JP. Best Pract. Res. Clin. Rheumatol. 2019; 33(2): 290-300.

Affiliation

Biomedical Research Centre, Hasselt University, Agoralaan, Gebouw D, Diepenbeek, 3590, Belgium; Department of Internal Medicine, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre +, P.O. Box 5800, AZ Maastricht, 6202, the Netherlands; Department of Internal Medicine, VieCuri Medical Centre, Tegelseweg 210, BL Venlo, 5912, the Netherlands. Electronic address: jvdbergh@viecuri.nl.

Copyright

(Copyright © 2019, Elsevier Publishing)

DOI

10.1016/j.berh.2019.04.005

PMID

31547984

Abstract

In view of the high imminent risk for subsequent fractures, evaluation as early as possible after the fracture will result in early decisions about drug treatment, fall prevention and nutritional supplements. Drug treatment includes anti-resorptive and bone forming agents. Anti-resorptive therapy with broad spectrum fracture prevention and early anti-fracture effects are the first choice. In patients with multiple or severe VFs, the bone forming agent teriparatide should be considered. Adequate calcium and vitamin D are needed in all patients, together with appropriate nutrition, including adequate protein intake.

Copyright © 2019 Elsevier Ltd. All rights reserved.

Language: en

Keywords

Drug treatment; Fall prevention; Imminent fracture risk; Nutrition